CN106754744B - Group I avian adenovirus strain of serum type 4 and application thereof - Google Patents
Group I avian adenovirus strain of serum type 4 and application thereof Download PDFInfo
- Publication number
- CN106754744B CN106754744B CN201611071875.6A CN201611071875A CN106754744B CN 106754744 B CN106754744 B CN 106754744B CN 201611071875 A CN201611071875 A CN 201611071875A CN 106754744 B CN106754744 B CN 106754744B
- Authority
- CN
- China
- Prior art keywords
- strain
- group
- avian adenovirus
- cphb03
- serotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a group I avian adenovirus strain of serotype 4 and application thereof, belonging to the field of microbial viruses. The serotype 4 avian adenovirus I of the invention is named as CPHB03 strain, and the preservation number is CCTCC NO: v201651. After the CPHB03 strain is inactivated, an adjuvant is added for emulsification, and the vaccine immune chicken is prepared, so that epidemic diseases caused by the serotype 4 avian adenovirus group I can be prevented. The CPHB03 strain has pathogenicity and strong toxicity to chickens and can be used as a challenge strain for efficacy test of the avian adenovirus vaccine group I. The serotype 4 avian adenovirus I HB03 strain has important application values in the aspects of vaccine production, epidemic disease prevention and control.
Description
Technical Field
The invention belongs to the field of microbial viruses, and particularly relates to a group I avian adenovirus strain of serotype 4 and application thereof.
Background
The group I avian adenovirus belongs to the family of adenoviridae and the genus of avian adenovirus. The representative strain of the group I avian adenovirus is lethal chick embryo orphan virus. They share a common group-specific antigen, of which there are 12 serotypes isolated from chickens (FAV1-12), two serotypes of turkeys (TAV1-2), three serotypes of geese (GAV1-3) and 1 serotype of ducks. Group I avian adenoviruses can cause epidemic diseases of birds of different degrees, and the cross-protection effect among serotypes is poor.
Recently, it has been reported that the serotype 4 avian adenovirus group I has enhanced virulence, causing severe economic loss due to outbreaks of epidemic diseases in China. In 2015, a plurality of chicken flocks in chicken farms are also attacked in Hubei, and some chickens die acutely. The autopsy finds that the pericardial hydrops, the liver is fragile and discolored, the kidney is enlarged, and the glandular stomach has reticular bleeding. Experiments such as virus separation identification, virus genome sequencing analysis, animal regression test and the like prove that the disease is caused by serotype 4 avian adenovirus group I. However, no commercial vaccine for preventing avian adenovirus group I and no commercial vaccine for preventing avian adenovirus group I of serotype 4 exist in China. The development of group I avian adenovirus vaccines is in the clinical or laboratory stage. The key to effectively prevent and control the epidemic disease is to obtain a vaccine strain with excellent production characteristics and to develop a vaccine for preventing the serotype 4 group I avian adenovirus as early as possible.
Disclosure of Invention
The invention aims to provide a serotype 4 avian adenovirus group I strain and application thereof.
The purpose of the invention is realized by the following technical scheme:
the invention relates to a group I avian adenovirus strain of serotype 4, which is named as CPHB03 strain, wherein CPHB03 strain is deposited in the China center for type culture Collection (deposition address: China, Wuhan university) at 9-20 days 2016, and is classified and named as group I avian adenovirus CPHB03Aviadenovirus CPHB03, and the deposition number is CCTCC NO: v201651.
The avian adenovirus I strain CPHB03 has strong toxicity, and can be used as a strong toxicity for attacking during the efficacy test of the avian adenovirus I vaccine.
The avian adenovirus I strain CPHB03 strain can be used for preparing avian adenovirus I vaccines.
A group I avian adenovirus vaccine comprises the group I avian adenovirus strain CPHB03 strain.
In conclusion, the serotype 4 avian adenovirus I CPHB03 strain can be used as a vaccine production strain and a vaccine inspection strain for producing a vaccine and preventing and controlling epidemic diseases.
The invention has the advantages and beneficial effects that: the invention inactivates the I group fowl adenovirus CPHB03 strain of serum 4 type, then mixes it with mineral oil adjuvant and emulsifies them to obtain the inactivated vaccine, and immunizes susceptible animals (chicken), 21 days after immunization, the geometric mean value of serum neutralizing antibody titer is about 10000. After 21 days of immunization, the mortality rate and the toxin expelling rate of the immunization group are obviously lower than those of the blank chicken challenge group. The results of serological research and challenge protection research show that the vaccine prepared from the CPHB03 strain can enable susceptible animals to generate neutralizing antibodies with higher titer, can resist lethal attack of the disease, and can obviously reduce the detoxification rate after infection.
Drawings
FIG. 1 is a diagram showing the results of genetic evolutionary analysis of group I avian adenovirus serotype 4 strain CPHB 03.
FIG. 2 is a graph showing the results of homology analysis of group I fowl adenovirus serotype 4 strain CPHB 03.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto.
Example 1 isolation, culture and characterization of serotype 4 avian adenovirus group I CPHB03 Strain
In 2015, laying hens in a certain chicken farm in Hubei have diseases, and some chickens die acutely. The autopsy finds that the pericardial hydrops, the liver is fragile and discolored, the kidney is enlarged, and the glandular stomach has reticular bleeding.
Taking the liver of the dead chicken aseptically, grinding the liver by using a mortar, adding sterilized normal saline into the liver, uniformly mixing the liver and the liver, transferring the sample into a 15mL centrifuge tube, centrifuging the sample at 3000rpm for 10min, and filtering and sterilizing the supernatant by using a 0.22 mu m filter to obtain the virus liquid for later use. Doubling the above virus liquid by 10 times-1、10-2、10-3、10-4、10-5、10-6、10-7、10-8Inoculating primary chick embryo liver cells with good growth vigor respectively according to the dilution, culturing at 37 ℃ for about 120 hours, freezing and collecting the culture with the highest dilution with cytopathy reaching about 70%, subpackaging, marking as F1 virus solution, and freezing and storing.
Doubling the F1-generation virus liquid by 10 times-1、10-2、10-3、10-4、10-5、10-6、10-7、10-8Inoculating primary chick embryo liver cells with good growth vigor respectively according to the dilution, culturing at 37 ℃ for about 120 hours, freezing and collecting the culture with the highest dilution with cytopathy reaching about 70%, subpackaging, marking as F2 virus solution, and freezing and storing.
The procedure above gave generation F3.
Doubling the F3-generation virus liquid by 10 times-1、10-2、10-3、10-4、10-5、10-6、10-7、10-8Respectively inoculating primary chick embryo hepatocytes with good growth vigor according to dilution, incubating at 37 ℃ for 1 hour, sucking and discarding virus solution, and adding 3Cell maintenance solution containing 1% agarose at 7 deg.C, solidifying agarose, and placing at 37 deg.C and 5% CO2Culturing in an incubator for about 120 hours, 10%-7And (3) selecting one independent plaque, namely F4 virus, from the diluted cell culture dish, wherein the independent visible plaque exists in the diluted cell culture dish, and freezing and thawing the independent plaque for later use.
Inoculating 0.1% (V/V) of F4 virus solution into primary chick embryo hepatocyte with good growth vigor, culturing at 37 deg.C for about 48 hr until cytopathic effect reaches about 70%, freezing and collecting cell culture, packaging, and freezing and storing as F5 virus solution. The virus liquid of F5 generation is tested according to the test method of exogenous virus in Chinese veterinary pharmacopoeia, and the result shows that the virus liquid of F5 generation has no exogenous virus pollution and is pure virus liquid. The cells are subcultured and amplified according to the method and are used for subsequent research.
The Hexon protein is the main antigen protein of the avian adenovirus and contains type-specific, group-specific antigen epitopes and neutralizing antigen epitopes. The relative conservation of the Hexon gene for encoding the Hexon protein in closely related avian adenoviruses can be used for determining the taxonomic position of the avian adenovirus strain in the avian adenovirus and determining the evolutionary relationship of the avian adenovirus strain and other strains. Designing a specific primer (table 1), segmenting (A, B, C three segments) to determine the sequence of the Hexon gene, and splicing A, B, C three segments to obtain the sequence of the Hexon whole gene. Viral DNA of F5 generation was extracted, PCR detection was performed using specific primers (Table 1), and the results were visualized by 1% agarose gel electrophoresis. The PCR product gene was sequenced and subjected to homology analysis and genetic evolution analysis. From the results (FIGS. 1 and 2), it was found that the isolated virus belongs to group I avian adenovirus, and has the closest homology to group I avian adenovirus of serotype 4 and the lower homology to other group I avian adenovirus of other types. Thus, the isolated virus was identified as a serotype 4 avian adenovirus group I and designated CPHB03 strain.
TABLE 1 specific primers
The serotype 4 avian adenovirus I CPHB03 strain is deposited in the China center for type culture Collection (deposition address: China, Wuhan university) at 2016, 9, 20 days, and is classified and named as avian adenovirus I CPHB03Aviadenovirus CPHB03, with the deposition number of CCTCC NO: v201651.
EXAMPLE 2 virulence assay for serotype 4 avian adenovirus group I CPHB03 Strain
1. Virulence of CPHB03 strain on chick embryo hepatocytes (virus content of CPHB03 strain)
Preparing chick embryo liver cells, laying 96-hole cell culture plates, culturing at 37 ℃ with 5% CO2Culturing for about 24 hours under the condition, and discarding the cell growth liquid in the 96-hole cell culture plate. Diluting F5-substituted CPHB03 strain virus solution with cell maintenance solution by 10 times, and taking 10-6、10-7、10-8、10-9The diluted virus solution was inoculated into 96-well cell culture plates at 0.1 mL/well, and 6 replicate wells per dilution, placed at 37 ℃ in 5% CO2Culturing in an incubator. 7 days after inoculation, the 96-well cell culture plate is observed under a microscope, the number of wells with and without cell lesions in each dilution is counted, and the virus content of the detected sample is calculated by a Reed-Muench method. The content of the CPHB03 strain F5 virus is 108.0TCID50/0.1mL。
The CPHB03 strain was assayed in several generations (F6-F13) in accordance with the above-mentioned method, and the results are shown in Table 2. The results show that the CPHB03 strain has high virus content, and the virus content from F5 generation to F13 generation is 108.0TCID500.1mL to 109.2TCID50Between 0.1mL, significantly higher than the serogroup I avian adenovirus strain of serotype 4 known in the prior art. As is known in the art, the antigen virus content in the vaccine of the epidemic disease mainly based on humoral immunity is an important index for determining the protective effect of the inactivated vaccine, and therefore, the application of the CPHB03 strain of the serotype 4 avian adenovirus group I to the vaccine is more advantageous.
TABLE 2 CPHB03 strain virus content in each generation
| Number of generations | The virus containsQuantity (TCID)50/0.1mL) |
| Generation F6 | 108.0 |
| Generation F7 | 108.5 |
| Generation F8 | 108.0 |
| Generation F9 | 109.2 |
| Generation F10 | 109.0 |
| Generation F11 | 109.2 |
| Generation F12 | 108.5 |
| Generation F13 | 109.0 |
2. Virulence of CPHB03 strain on susceptible animals (chickens)
Will 108.0TCID50/0.1mL、106.0TCID50/0.1mL、104.0TCID50/0.1mL、102.0TCID500.1mL of CPHB03 strain was inoculated intramuscularly to 10 SPF chickens of 42 days old, each 0.2 mL. The disease condition was observed and recorded. Collecting cotton swabs of larynx and cloaca on days 1, 3, 5, 7 and 10 after toxin elimination, and detecting the toxin elimination condition of larynx and cloaca.
Clinical symptoms of attack appear 2-5 days after challenge of test chickens, the symptoms are manifested as depressed spirit and reversed feather, part of chickens die 1-2 days after attack, and the immortal chickens gradually recover; the mortality rates of the groups are 8/10, 6/10, 5/10 and 6/10 respectively; the typical pericardial hydrops, fragile and discolored liver, swollen kidney and reticular bleeding of glandular stomach can be seen in the dead chicken by the autopsy examination. The toxin expelling rate is 10/10 within 10 days after toxin attack. The result shows that the CPHB03 strain has stronger toxicity and can be used as strong toxicity for attacking toxicity in the vaccine efficacy test.
Example 3 immunogenicity evaluation of serotype 4 avian adenovirus group I CPHB03 Strain
Has a virus content of 107.5TCID500.1mL of the CPHB03 strain virus solution was inactivated at 37 ℃ for 24 hours by adding a formaldehyde solution at a final concentration of 0.1% (v/v). Inoculating and culturing the chicken embryo liver cells for 16-24 hours by taking 0.5mL of inactivated antigen as F1 generation; culturing for 72 hours in the F1 generation, and inoculating chicken embryo liver cells cultured for 24 hours to obtain an F2 generation; no cytopathy was observed in F2 culture for 168 hours, indicating complete inactivation of the test antigen. Adding Tween 80 into the inactivated antigen to make Tween 80 account for 4% of the total volume, and mixing to obtain water phase; adding span 80 and aluminum stearate into the white oil to ensure that the span 80 accounts for 6 percent of the total volume, the mass-volume ratio of the aluminum stearate to the white oil is 1.5 percent, mixing, heating and dissolving, and sterilizing to obtain the oil phase. The ratio of water phase to oil phase (volume ratio) is 1:2, and the mixture is cut at high speed by a shearing machine to form oil emulsion vaccine.
40 SPF chickens of 21 days old are taken and randomly divided into 4 groups, each group comprises 10 SPF chickens, 1 group and 3 groups are injected with vaccines subcutaneously at the neck part, each group comprises 0.3mL, and 2 groups and 4 groups are non-immune control groups. On day 21 after inoculation, the neutralizing antibody titer of the serum of the immunized chicken was measured, and the geometric mean value of the neutralizing antibody titer of the serum was about 10000 (table 3). The geometric mean value of about 10000 is higher antibody titer obtained by one-time immunization, so that the CPHB03 strain has better immunogenicity.
TABLE 3 serum neutralizing antibody titers
| Neutralizing antibody titer (log10) | Mean. + -. standard deviation of | |
| |
4.4、4.4、3.6、4.0、4.5、4.0、4.5、3.5、4.4、3.6 | 4.1±0.4 |
| |
4.0、4.5、4.4、4.0、3.6、3.4、4.25、4.0、5.4、4.5 | 4.2±0.6 |
Injecting CPHB03 strain virus solution 10 into chickens of 1 and 2 groups by intramuscular injection on 21 days after inoculation6.0TCID500.1mL, 0.2mL each; 3. intramuscular injection of CPHB03 strain virus liquid 10 for 4 groups of chickens2.0TCID500.1mL, 0.2mL each. Observing for 14 days, and collecting cotton swabs of larynx and cloaca after 1, 3, 5, 7 and 10 days of toxin elimination, and detecting toxin elimination condition of larynx and cloaca. The death and detoxification are shown in Table 4. The result shows that the vaccine prepared from the CPHB03 strain can enable susceptible animals to generate neutralizing antibodies with higher titer, can resist lethal attack of the disease and can obviously reduce the detoxification rate after infection.
TABLE 4 death and detoxification
| Group of | Death rateExample (b) | Toxin expelling ratio on |
The toxin expelling proportion within 10 days after toxin expelling |
| 1 | 0/10 | 1/10 | 1/10 |
| 2 | 5/10 | 9/10 | 10/10 |
| 3 | 0/10 | 1/10 | 1/10 |
| 4 | 5/10 | 10/10 | 10/10 |
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
SEQUENCE LISTING
<110> Wuhanzhongbo biological shares GmbH
<120> group I avian adenovirus strain of serum type 4 and application thereof
<130>1
<160>6
<170>PatentIn version 3.3
<210>1
<211>26
<212>DNA
<213>Artificial
<220>
<223> A fragment upstream primer
<400>1
gggcgcctga agctgcaaca agatct 26
<210>2
<211>28
<212>DNA
<213>Artificial
<220>
<223> A fragment downstream primer
<400>2
cgcggcggtg ttgttggtgt agagttta 28
<210>3
<211>23
<212>DNA
<213>Artificial
<220>
<223> B fragment upstream primer
<400>3
cgggcatgaa cgtggtggtc gag 23
<210>4
<211>26
<212>DNA
<213>Artificial
<220>
<223> B fragment downstream primer
<400>4
ccgctgttgt ccgtggtagg ggtgta 26
<210>5
<211>28
<212>DNA
<213>Artificial
<220>
<223> C fragment upstream primer
<400>5
cgacggcgcc agcatcatct acaacgag 28
<210>6
<211>30
<212>DNA
<213>Artificial
<220>
<223> C fragment downstream primer
<400>6
ggccggtttg tacatattct cgtggttgac 30
Claims (4)
1. A group i avian adenovirus (avidenovirus) strain of serotype 4 characterized by: the preservation number is CCTCC NO: v201651.
2. Use of the strain of claim 1 as an attacking strain in a test for efficacy of a group i avian adenovirus vaccine.
3. Use of the strain of claim 1 for the preparation of a group i avian adenovirus vaccine.
4. A group i avian adenovirus vaccine, characterized by: comprising the strain of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611071875.6A CN106754744B (en) | 2016-11-29 | 2016-11-29 | Group I avian adenovirus strain of serum type 4 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611071875.6A CN106754744B (en) | 2016-11-29 | 2016-11-29 | Group I avian adenovirus strain of serum type 4 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106754744A CN106754744A (en) | 2017-05-31 |
| CN106754744B true CN106754744B (en) | 2020-04-10 |
Family
ID=58905459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611071875.6A Active CN106754744B (en) | 2016-11-29 | 2016-11-29 | Group I avian adenovirus strain of serum type 4 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106754744B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269892B (en) * | 2020-03-06 | 2023-07-11 | 哈尔滨科欣农业科技有限公司 | Group I4 type avian adenovirus DN strain, avian adenovirus inactivated vaccine, preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105368795A (en) * | 2015-12-14 | 2016-03-02 | 青岛易邦生物工程有限公司 | I-colony fowl adenovirus 4 strain and application thereof |
| CN105593364A (en) * | 2013-06-27 | 2016-05-18 | Kcav有限公司 | Novel fowl adenovirus and vaccine thereof |
| CN106065030A (en) * | 2016-08-02 | 2016-11-02 | 重庆三杰众鑫生物工程有限公司 | Yolk antibody of chicken inclusion body hepatitis and preparation method thereof |
| CN106119212A (en) * | 2016-07-01 | 2016-11-16 | 瑞普（保定）生物药业有限公司 | Aviadenovirus strain, inactivated vaccine and preparation method |
| CN107523556A (en) * | 2016-06-21 | 2017-12-29 | 普莱柯生物工程股份有限公司 | A kind of aviadenovirus strain, vaccine combination and its application |
-
2016
- 2016-11-29 CN CN201611071875.6A patent/CN106754744B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105593364A (en) * | 2013-06-27 | 2016-05-18 | Kcav有限公司 | Novel fowl adenovirus and vaccine thereof |
| CN105368795A (en) * | 2015-12-14 | 2016-03-02 | 青岛易邦生物工程有限公司 | I-colony fowl adenovirus 4 strain and application thereof |
| CN107523556A (en) * | 2016-06-21 | 2017-12-29 | 普莱柯生物工程股份有限公司 | A kind of aviadenovirus strain, vaccine combination and its application |
| CN106119212A (en) * | 2016-07-01 | 2016-11-16 | 瑞普（保定）生物药业有限公司 | Aviadenovirus strain, inactivated vaccine and preparation method |
| CN106065030A (en) * | 2016-08-02 | 2016-11-02 | 重庆三杰众鑫生物工程有限公司 | Yolk antibody of chicken inclusion body hepatitis and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| Clinicopathological characterization and genomic sequence differences observed in a highly virulent fowl aviadenovirus serotype 4;Pedro F. Vera-Hernandez等;《Avian pathology》;20160317;第45卷(第1期);第73-81页 * |
| Genetic characterization of novel fowl aviadenovirus 4 isolates from outbreaks of hepatitis-hydropericardium syndrome in broiler chickens in china;YanKe Liu等;《Emerging microbes & infections》;20161123;第5卷(第1期);第1-8页 * |
| 一株高致病性血清4型禽腺病毒的分离与鉴定;梁广成等;《中国家禽》;20161031;第38卷(第19期);第25-28页 * |
| 山东省血清4 型禽腺病毒的分离鉴定;于可响等;《中国动物传染病学报》;20161031;第24卷(第5期);第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106754744A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Antigenic variation of LaSota and genotype VII Newcastle disease virus (NDV) and their efficacy against challenge with velogenic NDV | |
| RU2547589C2 (en) | New avian astrovirus | |
| Toffan et al. | Diagnostic and clinical observation on the infectious bronchitis virus strain Q1 in Italy. | |
| JP6397539B2 (en) | Infectious bronchitis vaccine derived from IB-QX-like strain | |
| CN105543180A (en) | Isolation, identification and purification method and application of gene VII type Newcastle disease virus strain | |
| CN109136198B (en) | Recombinant fowl pox virus live vector vaccine for expressing chicken infectious anemia virus VP1 and VP2 genes | |
| CN103497934B (en) | Avian infectious bronchitis virus vaccine strain (HF2 strain) and application thereof | |
| Zhang et al. | Antibody responses induced by recombinant ALV-A gp85 protein vaccine combining with CpG-ODN adjuvant in breeder hens and the protection for their offspring against early infection | |
| CN108465107B (en) | Duck type 2 adenovirus and Muscovy duck parvovirus disease combined inactivated vaccine | |
| CN109207436B (en) | Group I type 4 avian adenovirus strain and application thereof | |
| CN112574958B (en) | H9 subtype avian influenza virus isolate and application thereof | |
| CN105802918B (en) | Chicken's infectious bronchitis nephritis strain and its vaccine composition, preparation method and application | |
| CN106754744B (en) | Group I avian adenovirus strain of serum type 4 and application thereof | |
| KR101102271B1 (en) | Attenuated Avian Infectious Bronchitis Virus and Vaccine for Avian Infectious Bronchitis Comprising the Same | |
| CN106794242B (en) | Broad-spectrum vaccine against avian reovirus | |
| CN104130981A (en) | Application of avian infectious bronchitis virus vaccine strain in preparation of inactivated vaccine | |
| CN109055320B (en) | Infectious bronchitis virus isolate and application thereof in vaccine preparation | |
| CN108939063B (en) | Muscovy duck triple inactivated vaccine | |
| CN114395536B (en) | Avian adenovirus type 4, 8 and 11 trivalent vaccine and preparation method and application thereof | |
| KR101092977B1 (en) | Avian Infectious Bronchitis Virus and Vaccine for Avian Infectious Bronchitis Comprising the Same | |
| WO2009143332A2 (en) | Poultry viral materials and methods related thereto | |
| CN110713987B (en) | Recombinant gene VII type Newcastle disease virus strain and vaccine composition, preparation method and application thereof | |
| CN103007271A (en) | Chicken subunit four-combination vaccine and preparation and application thereof | |
| Tarpey et al. | Onset of immunity following in ovo delivery of avian metapneumovirus vaccines | |
| CN112063596A (en) | Pigeon paramyxovirus type 1 PPMV-1/BJ-C strain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |